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IL-22-Aminoethyl diphenylborinate (2-APB) is a well-known effector of the store-operated Ca2+ entry of several cell
types such as immune cells, platelets and smooth muscle cells. 2-APB has a dual effect: potentiation at 1–5 μM
and inhibition at N30 μM. Unfortunately, it is also able to modify the activity of other Ca2+ transporters and, thus,
cannot be used as a therapeutic tool to control the leukocyte activity in diseases like inﬂammation. Previ-
ously, we have shown that SOCE potentiation by 2-APB depends on the presence of the central boron-
oxygen core (BOC) and that the phenyl groups determine the sensitivity of the molecule to inhibit and/or
potentiate the SOCE.
Wehypothesized that bymodifying the two phenyl groups of 2-APB,we could identifymore efﬁcient and speciﬁc
analogues. In fact, the addition ofmethoxyl groups to one phenyl group greatly decreased the potentiation ability
without any signiﬁcant effect on the inhibition. Surprisingly,when the free rotation of the twophenyl groupswas
blocked by a new hydrocarbon bridge, the BOCwas no longer able to potentiate. Furthermore, larger aryl groups
than phenyl also impaired the activity of the BOC. Thus, the potentiation site in the Ca2+ channel is not accessible
by the BOCwhen the lateral groups are too large or unable to freely rotate. However, these molecules are potent
inhibitors of store-operated calcium entry with afﬁnities below 1 μM, and they can block the activation of the
Jurkat T cells.
Thus, it is possible to characterize 2-APB analogues with different properties that could be the ﬁrst step in the
discovery of new immunomodulators. This article is part of a special issue entitled “Calcium Signaling in Health
and Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc
Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cytosolic calcium concentration increase is a common feature in the
initiation of biological processes such as cell activation, proliferation or
apoptosis [1]. It is usually due to the release of Ca2+ ions from the internal
stores, especially the endoplasmic reticulum (ER) and a massive entry of
extracellular Ca2+ ions by a process known as “store-operated calcium
entry” or SOCE. In a large number of non-excitable cells, this entry results
from the opening of a class of channels known as “store-operated calcium
channels” or SOCC. Although the SOCE of T lymphocyteswas described in
the 1980s, major progress has been made in the understanding of its ac-
tivation in the last decade with the discovery and characterization of two
proteins: the plasma membrane (PM) Orai1 protein, which forms the
pore of the SOCC [2], and the ERmembrane STIM1protein, which induces; SOCE, store-operated calcium
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33 1 69 15 58 93.the opening of the SOCC [3]. During the T cell activation, the T cell recep-
tor (TCR) stimulation induces the synthesis of inositol 1,4,5-trisphosphate
(IP3), which allows the release of Ca2+ ions trapped in the ER lumen
through IP3 receptors. This release causes the oligomerization of ERmem-
brane STIM1 proteins and theirmigration to ER-PM junctionswhere they
directly interact with Orai1 proteins, the pore-forming unit of the Ca2+
release-activated Ca2+ (CRAC) channels. This physical interaction allows
the opening of the channel and the massive entry of extracellular Ca2+
ions in a process known as the SOCE. The absence of functional Orai1 or
STIM1 proteins impairs the SOCE and is responsible for severe
combined immunodeﬁciencies [4]. In contrast under low agonist
concentration stimulation, additional Ca2+ entry could be activated [5].
In non-immune cells, SOCE is less prominent and often activated
together with other calcium entry pathways (example of neurons [6]).
In the immune system, pharmacological compounds acting on
Orai1/STIM1 proteins are theoretically interesting to control T cell func-
tions in order to be used as treatment for inﬂammation, auto-immune
diseases and graft rejection for example. Noteworthy, during the last
30 years, several laboratories have developed SOCE inhibitors, but
none of thesemolecules is used in therapy, mainly due to a lack of spec-
iﬁcity. However, since the discovery of the Orai1/STIM1 couple and its
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been boosted. Recently, Calcimedica, a company founded by some of
the Orai1 and STIM1 inventors, has announced the development of
an SOCE inhibitor already in phase 1 clinical trial to treat moderate
to severe plaque psoriasis (CM2489, structure not published).
Among all the known effectors of SOCE, we have focused our work on
2-aminoethoxy diphenylborinate (2-APB), which has unique properties:
at 1–5 μM, 2-APB potentiates the SOCE but inhibits it at N30 μM [7,8]. 2-
APB was ﬁrst described as an IP3 receptor inhibitor (IC50 42 μM [9]) and
is known to block the SERCA (IC50 91 μM [10]). Additionally, 2-APB was
shown to inhibit some members of the TRP family: TRPC1 in neuronal
cells (IC50 80 μM [11]), TRPC3 with a partial block at 30 μM in DT40
cells [12] and TRPC5 expressed in HEK293 cells (IC50 20 μM [13]). On
the other hand, 2-APB activates TRPV1, TRPV2 and TRPV3 with an EC50
between 34 and 129 μM [14]. Likewise, it has been shown in another
study that 2-APB has a dual activity on TRPM7 channels with a potentia-
tion at concentrations around 100 μM and an inhibition for N1 μM [15].
Despite its lack of speciﬁcity, we previously showed that the basic
molecule could be modiﬁed to give rise to analogues with distinct
properties [8]. Structurally, 2-APB is made of three parts: a central
boron-oxygen core, an ethanolamine and two phenyl groups. The
absence of the central boron-oxygen core totally abolishes the potenti-
ation capacity of the molecules, showing that this part of the 2-APB
molecule is absolutely necessary for this ability [8]. On the other side,
the ethanolamine and the two phenyl groups are implied in the inhibi-
tion capacity. To better understand the functioning of SOCE and to de-
velop new regulators of the immune system, we need new molecules
with better selectivity and efﬁcacy. In this study, we based our work
on the role of the two phenyls in 2-APB activities. For this purpose, we
chose several 2-APB analogues with modiﬁcations such as the addition
of methoxy groups on one phenyl group, or replacement of the two
phenyls by thienyl or benzothienyl groups.
Previously, we have shown that even if the two aryl groups
(any functional group with an aromatic ring) play a role in this inhi-
bition process, they are also critical for the sensitivity of the SOCE for
the 2-APB analogue; thus, the more there are cycles in the analogue,
themore the SOCE is sensitive (Jurkat T cell SOCE is more sensitive to
diphenylborinic anhydride with 4 rings than to 2-APB with 2 rings
and to 2-aminoethoxy dibutylborinate with none [8]). In this work,
we kept the central boron-oxygen core BOC and the ethanolamine
parts intact and only changed the two aryl groups. All new compounds
were tested on Jurkat cell SOCE and not with an Orai1/STIM1 over-
expressing system. Indeed, the Jurkat cell SOCE has been intensively
studied by numerous groups, and its pharmacological and kinetic
properties are well established. Since the expression ratio between
Orai1 and STIM1 modiﬁes the pharmacological properties of the SOCE
[16], we preferred to investigate endogenous SOCE. In Jurkat cells,
SOCE is mostly due to Orai1 activation [17].
Results obtainedwith these new analogues showed that the 3D con-
formation of the two aryl groups is also important for the potentiation
ability of the analogues. It also gives rise to a very potent SOCE inhibitor.
As expected, some other changes in the parent molecule only modify
the sensitivity for potentiation and inhibition. Unfortunately, these
molecules, like 2-APB, lack speciﬁcity. However, even if they cannot be
used outside the laboratories, they could represent another step in the
discovery of new and more efﬁcient molecules to treat diseases where
the immune system is implied.
2. Materials and methods
2.1. Cell lines
The Jurkat E6.1 (acute T cell leukemia) cell line was maintained
in RPMI-1640 medium (Lonza, Verviers, Belgium) supplemented with
10% fetal calf serum and 2 mM Glutamax® (Invitrogen, Cergy-pontoise,
France) at 37 °C in a 5% CO2 humidiﬁed atmosphere.2.2. Measurement of cytosolic Ca2+ concentration ([Ca2+]cyt)
The cytosolic Ca2+ concentration was recorded by a ﬂuorimetric ratio
technique. Cells were centrifuged and resuspended in phosphate-
buffered saline medium (PBS, Cambrex, Belgium) supplemented with
1 mg/ml bovine serum albumin (Sigma, Saint Quentin Fallavier, France)
under gentle agitation. The ﬂuorescent indicator indo-1 was loaded by
incubating the cells at room temperature for 1 h with 4 μM indo-1-AM
(Invitrogen/Molecular Probes, Eugene, USA). Cells were then spun down
and resuspended in HEPES-buffered saline (HBS) medium without
CaCl2 (in mM): 135 NaCl, 5.9 KCl, 1.2 MgCl2, 11.6 HEPES, 11.5 glucose,
pH 7.3, adjusted with NaOH.
One million cells were put in a 1-cmwidth to 3-ml quartz cuvette
and inserted in a spectroﬂuorophotometer (RF-1501 Shimadzu
Corporation, Japan), equipped with a thermostated (37 °C) cuvette
holder. An ultraviolet light of 360 nm was used for excitation of
indo-1, and emissions at 405 and 480 nmwere recorded. Background
and autoﬂuorescence of the cells were subtracted from the values
measured at 405 and 480 nm. The maximum indo-1 ﬂuorescence
ratio (Rmax) was obtained by adding 1 μM ionomycin to the bath in
the presence of 10 mM CaCl2. Minimum ﬂuorescence ratio (Rmin) was
determined from cells suspended in a calcium-free medium following
the depletion of residual Ca2+ by 5 mM EGTA. All the measures were
sent to a personal computer and analyzed. [Ca2+]cyt was calculated ac-
cording to the equation [Ca2+]cyt = Kd (R− Rmin) / (Rmax− R), where
Kd is the apparent dissociation constant of indo-1 for Ca2+ (250 nM,
[18]), and R is the ratio of ﬂuorescence value at 405 nM over the
ﬂuorescence at 480 nm [18].
To induce SOCE, cells were treated with 1 μM TG in the absence
of external Ca2+. After 10 min, 1 mM CaCl2 was added. For dose–
response curves, the peak [Ca2+]cyt was measured and expressed
as a percentage of peak [Ca2+]cyt measured in the absence of the
2-APB analogue.
To test the effects of 2-APB and its analogues on the Ca2+ release
by the ER, the Jurkat T cells were stimulated by 10 μg/ml phytohe-
magglutinin (PHA) instead of TG, still in the absence of extracellular
Ca2+. PHA cross-links the T cell receptor (TCR), inducing the synthe-
sis of IP3 and Ca2+ release through IP3 receptors. Cells were pre-
treated for 5 min with 2-APB or an analogue, and then stimulated
by PHA.2.3. IL-2 assay
Onemillion Jurkat cells perwell were incubated in 24-well plates for
24 hwith 10 μg/ml phytohemagglutinin and 0 or 10 μMof certain 2-APB
analogues. Then supernatants were collected and IL-2 amounts were
quantiﬁed using a Quantikine Human IL-2 Immunoassay from R&D
Systems (R&D Systems Europe, Lille, France).2.4. Chemicals
2-Aminoethyl diphenylborinate (1, 2-APB), 2-aminoethoxy dibutyl-
borate (4, 2-ABB) and other chemicals were from Sigma (Saint Quentin
Fallavier, France), except 2-aminoethyl 3-methoxyphenyl(phenyl)
borinate (2, “methoxy-APB”)), 2-aminoethyl 3,4-dimethoxyphenyl
(phenyl)borinate (3, “dimethoxy-APB”), 2-aminoethyl di(2-thienyl)
borinate (5, “dithienyl-APB”), 2-aminoethyl 3-chloro-2thienyl (2-
thienyl)borinate (6, “chloro-dithienyl-APB”), 2-aminoethyl di(-
benzothien-2-yl)borinate (7, “dibenzothienyl-APB”) and 2-(10,11-
dihydro-5H-dibenzo[b,f]borepin-5yloxyl)ethylamine (8 “cyclic-APB”),
which were from Specs (Delft, The Netherlands). Structures of these
molecules were drawn by Marvin software (http://www.chemaxon.
com/products/marvin/) and are depicted in Fig. 1. Abbreviated trivial
names (“ ”) were used for simplicity.
Fig. 1. Structure of 2-APB (compound 1) and 2-APB analogues (compounds 2 to 8) used in this study (see method section).
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The comparison of the effects of the 2-APB analogueswas performed
using the Student's t-test. Differenceswith a p value b0.05 were consid-
ered statistically signiﬁcant. Dose–response curves were compiled from
at least 5 repeats.
3. Results
The different 2-APB analogues used in this study could be grouped
according to the type of aryl group modiﬁcation: the addition of
methoxyl group(s) on one phenyl, the substitution of the two phenyl
groups by thienyl or benzothienyl groups and the insertion of a
hydrocarbon bridge between the two phenyl groups.
3.1. Addition of methoxyl groups to one phenyl group
Minor changes in the 2-APB structure are known to modify the
properties of the molecule on SOCE. However, as mentionned by
Dobrydneva et al. [19], changes in the phenyl groups without changing
the ethanolamine group have not been explored.
To visualize the SOCE, we treated the Jurkat cells with 1 μM
thapsigargin (TG) in a Ca2+-freemedium during 10min: this treatment
allows the release of Ca2+ ions from the ER, and subsequently the
opening of the store-operated Ca2+ channels (SOCC). The addition
of 1mMCaCl2 then induced an increase of the cytosolic Ca2+ concentra-
tion ([Ca2+]cyt) due to the entry of Ca2+ ions through SOCC. As pre-
viously shown [7,8], 2-APB had a dual effect: potentiation at 5 μM
(217% ± 20%) and inhibition for concentrations N30 μM (Fig. 2A
and C).
The ﬁrst two analogues used are 2-APBs where one (Fig. 1, com-
pound 2, trivial name “methoxy-APB”) or two (Fig. 1, compound 3
“dimethoxy-APB”) methoxyl group(s) was (were) added only on one
phenyl group. The two “methoxylated” compounds still displayed the
dual effect on the Jurkat SOCE as 2-APB, but with a signiﬁcant decrease
of the potentiation efﬁcacy (Fig. 2B and C). Even if the full inhibitionwas
not changed (obtained for concentrations N30 μM), the potentiation
efﬁcacy was reduced at the optimal concentration of 5 μM: 160% ±
9% (methoxy-APB), 127% ± 5% (dimethoxy-APB) vs. 217% ± 21%(2-APB, Fig. 2C). Thus, the modiﬁcation of one phenyl group of the
2-APB could have a major impact on the potentiation capacity of
the molecule even if the boron-oxygen core is still present.
3.2. Substitution of the phenyl by thienyl groups
In a previous work, we have shown that the replacement of the
two phenyls by smaller groups like butyls (Fig. 1, compound 4, 2-ABB)
only induced a loss of sensitivity, but the potentiation capacity and
amplitude were unchanged [8].
Compound 5 (“dithienyl-APB”) is a 2-APB analogue with two
thienyls instead of phenyls (Fig. 1). This compound was also able to
potentiate and inhibit the Jurkat cell SOCE like 2-APB (Fig. 3A and B).
The maximal potentiation of SOCE was obtained with 30 μM (186% ±
15%) and full inhibition at N300 μM (Fig. 3B). The activity of dithienyl-
APB was very similar to the effect of 2-ABB. Thus, dithienyl-APB is as
efﬁcient as 2-APB in potentiating and inhibiting the SOCE; however,
its afﬁnity is much weaker.
The presence of a chlorine atom on one thienyl group (Fig. 1,
compound 6 “thienyl-chlorothienyl-apb”) totally abolished the
potentiation of the SOCE by the dithienyl-APB (Fig. 3B). The intro-
duction of a chlorine atom is able to block the potentiation capacity
of the BOC.
3.3. Substitution of the phenyl by benzothienyl groups
The compound 7 is a 2-APB where the two phenyl groups are
replaced by two larger benzothienyls (Fig. 1 “dibenzothienyl-APB”)
and therefore is larger than 2-APB. Surprisingly, dibenzothienyl-APB
wasunable to potentiate the SOCE, although it contains a BOC.However,
inhibitionwas complete at a concentration N1 μM(Fig. 4A and C). The ﬁt
of the dose–response curve allowed the calculation of an IC50 ~0.4 μM
(Fig. 4C).
3.4. A second link between the two phenyl groups
Compound 8 is a 2-APB molecule with a second link (−CH2-CH2−)
between the two phenyl groups (Fig. 1, “cyclic-APB”). This bridge
impairs the free rotation of the two phenyl groups.
AB
C
Fig. 2. 2-APB, methoxy-APB and dimethoxy-APB have a dual effect on Jurkat T cell SOCE.
(A and B) Representative measurement of cytosolic Ca2+ variation using indo-1
ﬂuorescence. In the absence of extracellular Ca2+ ions, cells were treated for 10 min
with 1 μM TG to allow Ca2+ release from ER and the opening of SOC. After 10 min, 1
mM CaCl2 was re-added allowing Ca2+ entry through SOC. Different 2-APB (A) or
dimethoxy-APB (B) concentrationswere applied 30 s prior CaCl2. Error barswere omitted
for clarity (SEM b 70 nM). (C) Dose–response curve of 2-APB, methoxy-APB and
dimethoxy-APB on Jurkat cell SOCE. Experiments were done as in A and B, and peak
[Ca2+]cyt was expressed as % of peak [Ca2+]cyt obtained in the absence of 2-APB or
analogues. The 2-APB and analogues were added 30 s prior to CaCl2 addition.
A
B
Fig. 3. Dithienyl-APB has a dual effect on Jurkat SOCE while chloro-dithienyl-APB is
only inhibiting. (A) Experiments were done as in Fig. 2, except that dithienyl-APB
was used at different concentrations instead of 2-APB (the same was done with
chloro-dithienyl-APB and 2-ABB but not shown). (B) Dose–response curve of 2-APB,
chloro-dithienyl-APB, 2-ABB and dithienyl-APB on Jurkat cell SOCE. Dose–response
curve was prepared as in Fig. 2C.
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SOCE despite the presence of the BOC in its structure (Fig. 4B and C).
The ﬁt of the dose–response curve allowed the calculation of an
IC50 ~ 3 μM (Fig. 4C).3.5. Ca2+ release by the ER is decreased by the new 2-APB analogues
The main impairment for the use of 2-APB in therapies is its lack of
speciﬁcity. In fact, 2-APB was ﬁrst described as an IP3R blocker [9]. To
study the speciﬁcities for SOCE of these new analogues, we measured
the Ca2+-release from the ER after stimulation of Jurkat cells with
10 μg/ml phytohemagglutinin (PHA) in the absence of extracellular
Ca2+. Thus, all the [Ca2+]cyt variations are due to the Ca2+ release
from the ER without any Ca2+ inﬂux.
In these conditions, [Ca2+]cyt quickly increased by ~35 nM and then
decayed slowly due to the Ca2+ ion extrusion by PMCA andNCXactivityand also Ca2+ uptake by SERCA into the ER (Fig. 5). The two
“methoxylated” 2-APB analogues, used at the potentiating concen-
tration of 3 μM, were added 5 min prior to PHA and clearly decreased
the PHA-induced Ca2+ release by ~85% (Fig. 5B). The other com-
pounds were used at fully inhibiting concentrations. They were all
efﬁcient inhibitors of the Ca2+ release, with a complete inhibition
for the dibenzothienyl-APB (Fig. 5A and B).3.6. The SOCE inhibiting 2-APB analogues decrease the IL-2 synthesis by
PHA-stimulated Jurkat cells
When Jurkat T cells are stimulated by PHA, IL-2 is synthesized and
secreted [20]. The inhibition of the PHA-induced Ca2+ inﬂux by
SKF96365 impairs the IL-2 synthesis [20].
We next tested the biological activity of the two best inhibitors of
SOCE we characterized, which we used at 10 μM. Without stimulation,
Jurkat cells did not produce any detectable amount of IL-2 (Fig. 6). On
the contrary, PHA stimulation induced the synthesis of ~1 μg IL-2/ml
after 24 h. Cyclic-APB and dibenzothienyl-APB inhibited IL-2 synthesis
by ~75% and 98%, respectively (Fig. 6).4. Discussion
Concentration dependent potentiation and inhibition of SOCE by
2-APB is frequently used to characterize calcium inﬂux in leukocytes
and other cells. To obtain compounds with therapeutic use, new an-
alogues of 2-APB are required. They should be either potentiating or
inhibiting and their speciﬁcity for SOCE must be improved. To this
end, understanding the functional effects of the structural features
of 2-APB would allow a rational design of new analogues.
AB
C
Fig. 4. Cyclic-APB and dibenzothienyl-APB are strong SOCE inhibitors. (A and B)
Experiments were done as in Fig. 2, except that cyclic-APB (A) or dibenzothienyl-
APB were used at different concentrations instead of 2-APB. (C) Dose–response
curve of 2-APB, cyclic-APB and dibenzothienyl-APB on Jurkat cell SOCE. Dose–
response curve was prepared as in Fig. 2C.
B
A
Fig. 5. All 2-APB analogues are ER Ca2+ release inhibitors. (A) Representative
measurement of cytosolic Ca2+ variation using indo-1 ﬂuorescence. Cells were
treated for 10 min with PHA 10 μg/ml to allow Ca2+ release from ER by IP3R in the
absence of extracellular Ca2+ ions. 2-APB analogues were added to cells in a 5-min
pretreatment before the addition of PHA. (B) Bar graph comparing the peak
Δ[Ca2+]cyt induced by PHA in absence and presence of the different 2-APB analogues.
Data are mean ± SEM from 5 independent experiments.
Fig. 6. Cyclic-APB and dibenzothienyl-APB are inhibitors of the IL-2 synthesis by PHA-
stimulated Jurkat cells. One million Jurkat cells were incubated 24 h with 10 μg/ml
PHA and 0 or 10 μM of cyclic-APB or dibenzothienyl-APB. Then supernatants were
collected and IL-2 amounts were quantiﬁed using an Elisa kit from R&D Systems.
Data are mean ± SEM from 5 independent experiments.
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We found that small modiﬁcations on the two phenyls of the
molecule may be sufﬁcient to suppress potentiation and increase
the inhibition capacity.
The potentiation and inhibition of SOCE by 2-APB and its analogues
may rely on binding to the same protein, most likely the channel
Orai1, or even on the same binding site. However, most authors favor
the idea of multiple binding sites and perhaps multiple target proteins,
for example, the channel and its regulator STIM [7,21,22]. We observe
that small changes in the phenyl groups, such as 2-APB vs. cyclic-APB
and dibenzothienyl-APB vs. dithienyl-APB, determine the potentiation
activity without affecting the inhibitory action. These data are clearly
in favor of a potentiation site which is not accessible for all compounds
and which is distinct from the inhibition site.
Cyclic-APB is unable to potentiate Jurkat cell SOCE. Thus, the
presence of the supplementary ethyl bridge (−CH2-CH2−) between
the two phenyl groups impairs the potentiation capacity of the
molecule. The absence of potentiation by the cyclic-APB is surprising
as it still possess the BOC, which is required for the potentiation of theSOCE [8]. Thus, the BOC appears unfunctional. Two explanations can
be suggested: (1) Potentiation may require that the two phenyls are
in a certain orientation with respect to the BOC or with respect to
each other; the ethyl bridge between these two phenyls impairs the
free rotation of the two groups, restricting the conformation of themol-
ecule and thereby prevents the potentiating activity. (2) The BOC must
reach the potentiating site of SOC channel, but the link between the
phenyls prevents the access of the BOC core to the site of potentiation.
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contains the BOC linked to two benzothienyl groups, which can freely
rotate. Surprisingly, the potentiation was absent while a strong inhibi-
tion of Jurkat cell SOCE occurred with an IC50 = 0,4 μM. The absence
of potentiation may be explained by the steric crowding caused by the
two larger benzothienyl groups that prevent the access of the BOC to
the potentiation site. Remarkably, the smaller thienyl groups found in
dithienyl-APB donot prevent potentiation by this compound but reduce
its apparent afﬁnity compared to 2-APB. Interestingly, thienyl-APB ac-
tivity is very similar to 2-ABB's, meaning the target of these molecules
cannot distinguish between thienyl and butyl groups. Thus, analogues
with smaller lateral groups than phenyl probably have the same proﬁle
of dual effect on SOCE. However, the introduction of a chlorine atom
on one thienyl group totally abolishes the potentiation ability of the
molecule. Thus, the electronegativity of this atom could perturb the
thienyl group and thereby affect the BOC.
Smaller modiﬁcations in one of the two phenyls by adding 1 or 2
methoxy group(s) (methoxy- and dimethoxy-APB) appear to decrease
gradually the potentiating activity on Jurkat cell SOCE observed
with 2-APB. In this case, the methoxy group may affect the BOC of the
molecule because of its electronegativity. Consequently, the perturbed
BOC is less efﬁcient in potentiating the Jurkat cell SOCE. The two
“methoxylated” analogues kept the potentiation capacity at the same
concentration as 2-APB (5 μM) but with a weaker intensity.
We proposed in a previous study a correlation between the number
of rings (true rings plus the ring created by the internal coordinate
between N and B) and the potentiation/inhibition activity [8]. This cor-
relation is conﬁrmed by the analogues cyclic-APB and dibenzothienyl-
APB having 3 (+1 internal coordinate) and 4 (+1) rings respectively
compared to 2 (+1) rings for 2-APBwith a corresponding shift towards
stronger afﬁnity for SOCE inhibition. Thus, the number of rings plays a
role in the sensitivity of the molecule.
The most sensitive inhibitor is dibenzothienyl-APB. Its increased
inhibition ability may be due to the stable attachment of the molecule
to the inhibitory site via the benzothienyl group that could constitute
a kind of hook and strengthen the inhibition capacity. Dibenzothienyl-
APB is probably the most interesting molecule among the new 2-APB
analogues we characterized: indeed with an IC50 b 1 μM, this molecule
is signiﬁcantly more potent than the classical SOCE inhibitor SKF96365
[20]. Thus, dibenzothienyl-APB is one of the best commercially available
inhibitors of the SOCE at that time.
Furthermore, when focused on analogues where the two phe-
nyls were replaced by simple rings or small hydrophobic groups
(dibenzothienyl-APB, dithienyl-APB and 2-ABB), the type (and the size)
of the groups seems to be important: the thienyl group (in dithienyl-
APB) is as efﬁcient as the “no-ring” group = butyl (in 2-ABB), whereas
the larger benzothienyl groups are more efﬁcient. It implies that
either the inhibition abilities of these molecules are due to the etha-
nolamine (free or forming the N-B internal coordinate), or butyl and
thienyl have the same efﬁcacy. 2-APB with two six carbon-based
cycles is more efﬁcient. The nature of the lateral amine group plays
a role in the inhibition ability of 2-APB analogues on the Ca2+ release
[19]. Thus, in 2-APB, the two phenyls and the ethanolamine groups
are implied in the inhibitory capacity.
The two “methoxylated” analogues both inhibit in the samemanner
as 2-APB at concentrations above 30 μM. However, their potentiation
capacity is reduced, which consolidates our hypothesis that the potenti-
ating and inhibitory sites on SOC channel are separated. When both
phenyl groups are modiﬁed with one methoxyl group each, the inhibi-
tion of SOCE in CHO cells was actually weaker than with 2-APB [23].
However, 2-APB did not potentiate SOCE in the CHO cell. It would be in-
structive to use that compound in cells where 2-APB potentiates SOCE.
Prakriya et al. [7] suggested that 2-APB monomers may be re-
sponsible for potentiation and dimers, which are formed at higher
concentrations, could be responsible for inhibition of SOCE. Interestingly,
screening of 2-APB analogues identiﬁed more potent inhibitors of SOCEcontaining two BOCs like a dimer [23]. Our data show that potentiation
activity may be lost with some monomers. However, 2-APB and all the
BOC-containing analoguesmay formdimers by intermolecular coordina-
tion bonds between the amino groups of one monomer and the boron
atom of the other monomer [8,19]. It is not clear, which percentage
of 2-APB or the analogues is present as dimers under physiological con-
ditions. We do not know whether the phenyl modiﬁcations described
here inﬂuence the proportion of dimers.
The effect of the 2-APB analogues on Ca2+-release from the ER was
also investigated in this work to detect changes in their speciﬁcity.
The results demonstrated that all themolecules described here also tar-
get the IP3R and inhibit Ca2+-release from the ER at concentrations
where they inhibit or potentiate SOCE. Consequently, modiﬁcations on
the phenyl ring are not sufﬁcient to prevent interference with the
IP3R. Since most articles on 2-APB analogues examine calcium ﬂux
in one particular cell-type, it remains to be seen whether different
cells containing different isoforms of the IP3R have distinct sensitivities
for these analogues. 2-APB is clearly inhibiting IP3Rs with different
efﬁciency in various cell types [24].
The synthesis of IL-2 by the stimulated - T lymphocytes is absolutely
required for their proliferation in an autocrine process [20]. When we
used a concentration of 10 μM, cyclic-APB decreased the Ca2+ release
by 80%–93% (Fig. 6) and the Ca2+ inﬂux by a ~90% (Figs. 2 and 4): this
level of inhibition is not enough to block totally the synthesis of IL-2,
which is “only” reduced by 75%. On the contrary, dibenzothienyl-APB
is a strong inhibitor of the two Ca2+ ﬂuxes: N99% and N98% of the
Ca2+ release and the inﬂux respectively, impairing the synthesis of
IL-2 and the activation of the Jurkat cell. This shows that larger aryl
cycles than phenyl could provide more efﬁcient compounds to inhibit
cell activation.
Analyzing the structure of the 2-APB analogues using Marvin
software (http://www.chemaxon.com/products/marvin/) suggests
that the ability to potentiate requires two conditions: (1) the presence
of a boron-oxygen core in the molecule and (2) the ability of the two
lateral aryl groups to rotate freely around their bound to the boron
atom. These conditions are met by methoxy-, dimethoxy- and thienyl-
APB. However, the size of the aryl groups could impair the potentiation
ability due to the non-accessibility of the boron-oxygen for the
potentiation site.5. Conclusions
Our results show that the potentiation activity of 2-APB analogues is
highly sensitive tomodiﬁcations of the phenyl groups.We characterized
two potentially interesting molecules: cyclic-APB and dibenzothienyl-
APB. Contrary to 2-APB, these two molecules are only inhibiting with
better sensitivity than 2-APB (IC50 of 3 and 0.4 μM, respectively).
These compounds are added to a list of products that allow a better
characterization of calcium inﬂux in leukocytes, give more information
about the SOCE mechanism and represent the ﬁrst step for the
development of new immunomodulators that could be used in
the clinic.References
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